Related Experiment Video
Updated: May 16, 2026
06:13
Randomized Controlled Trial to Study the Acute Effects of Strength Exercise on Insulin Sensitivity in Obese Adults
Published on: December 1, 2023
Pharmaceutical care program for type 2 diabetes patients in Brazil: a randomised controlled trial
Aline Oliveira Magalhães Mourão1, Wandiclécia Rodrigues Ferreira, Maria Auxiliadora Parreiras Martins
1Post-Graduate Program in Pharmaceutical Sciences, School of Pharmacy, Federal University of Ouro Preto, Ouro Preto, Brazil.
International Journal of Clinical Pharmacy
|November 20, 2012
Summary
A pharmaceutical care program significantly improved glycemic control in Brazilian type 2 diabetes patients. This intervention reduced hemoglobin A1C and improved lipid profiles, highlighting its value in managing diabetes.
Area of Science:
- Endocrinology and Metabolism
- Public Health
- Pharmaceutical Sciences
Background:
- Type 2 diabetes in Brazil is characterized by high rates of poor glycemic control, with approximately 73% of patients exhibiting elevated hemoglobin A1C levels.
- Pharmaceutical care programs have demonstrated potential benefits in improving health outcomes for patients with type 2 diabetes.
Purpose of the Study:
- To assess the impact of a structured pharmaceutical care program on key metabolic markers in hyperglycemic type 2 diabetes patients.
- Specifically, the study aimed to evaluate changes in blood glucose, blood pressure, and lipid profiles.
Main Methods:
- An open-label, randomized controlled trial was conducted over six months across six primary care units in Ouro Preto, Brazil.
- Participants (aged ≥18 years) with type 2 diabetes on oral antidiabetic medications and hemoglobin A1C ≥7% were randomized to receive either usual care or usual care plus pharmaceutical intervention.
- The primary outcome measure was the change in hemoglobin A1C.
Main Results:
- The intervention group (n=50) achieved a significant reduction in hemoglobin A1C (-0.6%) compared to the control group (0.7%, p=0.001).
- Significant improvements were observed in the intervention group for fasting plasma glucose, total cholesterol, LDL cholesterol, triglycerides, and systolic blood pressure.
- The study also noted a significant increase in HDL cholesterol and greater use of lipid-modifying agents and platelet aggregation inhibitors in the intervention group.
Conclusions:
- Pharmaceutical care programs show significant potential for reducing hemoglobin A1C levels in type 2 diabetes patients within the Brazilian healthcare system.
- These programs can foster the rational use of medications, contributing to better overall management of type 2 diabetes.
Related Concept Videos
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:22Diabetes Mellitus: Type 2 and Gestational
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
01:26Type II Diabetes I: Introduction
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
01:24Type II Diabetes II: Pathophysiology
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
01:25Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...
01:26Type I Diabetes II: Pathophysiology
Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...